Tango Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TNGX Nasdaq 2830 www.tangotx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tango Therapeutics, Inc.

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data - Oct 26th, 2026 8:41 am
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug - Oct 23rd, 2026 2:06 pm
Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate - Oct 23rd, 2026 10:06 am
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? - Oct 23rd, 2026 9:36 am
Tango Therapeutics Sinks 13% on Pancreatic Cancer Data It Says “Surpass Any Published PDAC Datasets” - Oct 23rd, 2026 8:59 am
Tango Therapeutics stock falls despite positive cancer trial data - Oct 23rd, 2026 6:04 am
Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy - Oct 23rd, 2026 4:30 am
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage - Oct 21st, 2026 10:30 am
Tango Therapeutics (TNGX) Stock Looks Fully Valued After A 252% Run - Oct 20th, 2026 7:16 pm
Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? - Oct 20th, 2026 10:34 am
Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 - Oct 16th, 2026 5:00 am
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report? - Sep 10th, 2026 9:30 am
Tango Therapeutics (TNGX) At 3.7x P B As Pullback Tests Whether It Looks Pricey - Sep 4th, 2026 1:08 am
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 3rd, 2026 2:05 pm
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference - Sep 1st, 2026 5:00 am
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer - Aug 27th, 2026 11:00 am
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses - Aug 12th, 2026 8:46 am
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Aug 11th, 2026 5:00 am
Tango Therapeutics Announces Executive Chair Transition - Aug 6th, 2026 4:24 pm